The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18
Open accessAbstract
Sensitive high-throughput neutralization assays, based upon pseudoviruses carrying a secreted alkaline phosphatase (SEAP) reporter gene, were developed and validated for human papillomavirus (HPV)16, HPV18, and bovine papillomavirus 1 (BPV1). SEAP pseudoviruses were produced by transient transfection of codon-modified papillomavirus structural genes into an SV40 T antigen expressing line derived from 293 cells, yielding sufficient pseudovirus from one flask for thousands of titrations. In a 96-well plate format, in this initial characterization, the assay was reproducible and appears to be as sensitive as, but more specific than, a standard papillomavirus-like particle (VLP)-based enzyme-linked immunosorbent assay (ELISA). The neutralization assay detected type-specific HPV16 or HPV18 neutralizing antibodies (titers of 160-10240) in sera of the majority of a group of women infected with the corresponding HPV type, but not in virgin women. Sera from HPV16 VLP vaccinees had high anti-HPV16 neutralizing titers (mean: 45000; range: 5120-163840), but no anti-HPV18 neutralizing activity. The SEAP pseudovirus-based neutralization assay should be a practical method for quantifying potentially protective antibody responses in HPV natural history and prophylactic vaccine studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line.
Boukamp, P., Petrussevska, R. T., Breitkreutz, D., Hornung, J., Markham, A., & Fusenig, N. E. (1988) · The Journal of cell biology · doi:10.1083/jcb.106.3.761 · Cited by 4,170
Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective
Bosch, F. X., Manos, M. M., Munoz, N., Sherman, M., Jansen, A. M., Peto, J., Schiffman, M. H., Moreno, V., Kurman, R., Shan, K. V., et al. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.11.796 · Cited by 3,370
A Controlled Trial of a Human Papillomavirus Type 16 Vaccine
Koutsky, L. A., Ault, K. A., Wheeler, C. M., Brown, D. R., Barr, E., Alvarez, F. B., Chiacchierini, L. M., & Jansen, K. U. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020586 · Cited by 1,602
Koutsky, L. A., Holmes, K. K., Critchlow, C. W., Stevens, C. E., Paavonen, J., Beckmann, A. M., DeRouen, T. A., Galloway, D. A., Vernon, D., & Kiviat, N. B. (1992) · New England Journal of Medicine · doi:10.1056/nejm199210293271804 · Cited by 943
Chapter 1: Human Papillomavirus and Cervical Cancer--Burden and Assessment of Causality
Bosch, F. X., & de Sanjose, S. (2003) · JNCI Monographs · doi:10.1093/oxfordjournals.jncimonographs.a003479 · Cited by 826
Suzich, J. A., Ghim, S. J., Palmer-Hill, F. J., White, W. I., Tamura, J. K., Bell, J. A., Newsome, J. A., Jenson, A. B., & Schlegel, R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.25.11553 · Cited by 668
Harro, C. D., Pang, Y.-Y. S., Roden, R. B. S., Hildesheim, A., Wang, Z., Reynolds, M. J., Mast, T. C., Robinson, R., Murphy, B. R., Karron, R. A., et al. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.4.284 · Cited by 607
Self-citationBreitburd, F., Kirnbauer, R., Hubbert, N. L., Nonnenmacher, B., Trin-Dinh-Desmarquet, C., Orth, G., Schiller, J. T., & Lowy, D. R. (1995) · Journal of Virology · doi:10.1128/jvi.69.6.3959-3963.1995 · Cited by 589
Self-citationEfficient Intracellular Assembly of Papillomaviral Vectors
Buck, C. B., Pastrana, D. V., Lowy, D. R., & Schiller, J. T. (2004) · Journal of Virology · doi:10.1128/jvi.78.2.751-757.2004 · Cited by 489
Self-citationVirus-like Particles of Bovine Papillomavirus Type 4 in Prophylactic and Therapeutic Immunization
KIRNBAUER, R., CHANDRACHUD, L. M., O'NEIL, B. W., WAGNER, E. R., GRINDLAY, G. J., ARMSTRONG, A., McGARVIE, G. M., SCHILLER, J. T., LOWY, D. R., & CAMPO, M. S. (1996) · Virology · doi:10.1006/viro.1996.0220 · Cited by 313
Self-citationA quantitative in vitro focus assay for bovine papilloma virus
Dvoretzky, I., Shober, R., Chattopadhyay, S. K., & Lowy, D. R. (1980) · Virology · doi:10.1016/0042-6822(80)90195-6 · Cited by 304
Self-citationOpalka, D., Lachman, C. E., MacMullen, S. A., Jansen, K. U., Smith, J. F., Chirmule, N., & Esser, M. T. (2003) · Clinical and Vaccine Immunology · doi:10.1128/cdli.10.1.108-115.2003 · Cited by 276
Roden, R. B., Greenstone, H. L., Kirnbauer, R., Booy, F. P., Jessie, J., Lowy, D. R., & Schiller, J. T. (1996) · Journal of Virology · doi:10.1128/jvi.70.9.5875-5883.1996 · Cited by 275
Self-citationKjær, S. K., Chackerian, B., van den Brule, A. J. C., Svare, E. I., Paull, G., Walbomers, J. M. M., Schiller, J. T., Bock, J. E., Sherman, M. E., Lowy, D. R., et al. (2001) · PubMed · Cited by 269
Self-citationChristensen, N. D., Dillner, J., Eklund, C., Carter, J. J., Wipf, G. C., Reed, C. A., Cladel, N. M., & Galloway, D. A. (1996) · Virology · doi:10.1006/viro.1996.0466 · Cited by 255
Zhou, J., Liu, W. J., Peng, S. W., Sun, X. Y., & Frazer, I. (1999) · Journal of Virology · doi:10.1128/jvi.73.6.4972-4982.1999 · Cited by 253
The serological response to papillomaviruses
Dillner, J. (1999) · Seminars in Cancer Biology · doi:10.1006/scbi.1999.0146 · Cited by 231
Papillomaviruses infect cells via a clathrin-dependent pathway
Day, P. M., Lowy, D. R., & Schiller, J. T. (2003) · Virology · doi:10.1016/s0042-6822(02)00143-5 · Cited by 230
Self-citationChristensen, N. D., Reed, C. A., Cladel, N. M., Han, R., & Kreider, J. W. (1996) · Journal of Virology · doi:10.1128/jvi.70.2.960-965.1996 · Cited by 220
Human papillomavirus—the most significant risk determinant of cervical intraepithelial neoplasia
Kjær, S. K., van den Brule, A. J. C., Bock, J. E., Poll, P. A., Engholm, G., Sherman, M. E., Walboomers, J. M. M., & Meijer, C. J. L. M. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960301)65:5<601::aid-ijc8>3.0.co;2-6 · Cited by 202
Leder, C., Kleinschmidt, J. A., Wiethe, C., & Müller, M. (2001) · Journal of Virology · doi:10.1128/jvi.75.19.9201-9209.2001 · Cited by 161
In vitro gene transfer using human papillomavirus-like particles
Touzé, A., & Coursaget, P. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.5.1317 · Cited by 160
Generation and neutralization of pseudovirions of human papillomavirus type 33
Unckell, F., Streeck, R. E., & Sapp, M. J. (1997) · Journal of Virology · doi:10.1128/jvi.71.4.2934-2939.1997 · Cited by 148
White, W. I., Wilson, S. D., Bonnez, W., Rose, R. C., Koenig, S., & Suzich, J. (1998) · Journal of Virology · doi:10.1128/jvi.72.2.959-964.1998 · Cited by 124
NHPV16 VLP Vaccine Induces Human Antibodies That Neutralize Divergent Variants of HPV16
Pastrana, D. V., Vass, W. C., Lowy, D. R., & Schiller, J. T. (2001) · Virology · doi:10.1006/viro.2000.0702 · Cited by 110
Self-citationPapillomavirus vaccines in clinical trials
Galloway, D. A. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00720-5 · Cited by 110
Immunity to oncogenic human papillomaviruses
Kónya, J., & Dillner, J. (2001) · Advances in cancer research · doi:10.1016/s0065-230x(01)82007-8 · Cited by 104
Kawana, K., Yoshikawa, H., Taketani, Y., Yoshiike, K., & Kanda, T. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.10298-10300.1998 · Cited by 80
Infectious human papillomavirus type 18 pseudovirions
Stauffer, Y., Raj, K., Masternak, K., & Beard, P. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1998.2113 · Cited by 77
Titration of HPV-11 Infectivity and Antibody Neutralization Can Be Measured In Vitro
Smith, L. H., Foster, C. A., Hitchcock, M. E., Leiserowitz, G. S., Hall, K., Isseroff, R., Christensen, N. D., & Kreider, J. W. (1995) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12321173 · Cited by 61
Papillomavirus-like particle based vaccines: cervical cancer and beyond
Lowy, D. R., & Schiller, J. T. (2001) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.1.4.571 · Cited by 61
Self-citationAssembly of Human Papillomavirus Type 16 Pseudovirions in Saccharomyces cerevisiae
Rossi, J. L., Gissmann, L., Jansen, K. U., & Müller, M. (2000) · Human Gene Therapy · doi:10.1089/10430340050015211 · Cited by 58
Stanley, M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802174-3.00013-8 · Cited by 33
Kahn, J. A., & Bernstein, D. I. (2003) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000068036.26828.13 · Cited by 24
Cited by
Correlates of protection induced by vaccination
Plotkin, S. A. (2010) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00131-10 · Cited by 1,745
“Antibody to papillomavirus can be measured by a pseudovirus-based neutralization assay, as well as by ELISA (131).”
MethodRoberts, J. N., Buck, C. B., Thompson, C. D., Kines, R., Bernardo, M., Choyke, P. L., Lowy, D. R., & Schiller, J. T. (2007) · Nature Medicine · doi:10.1038/nm1598 · Cited by 503
Self-citationCarrageenan is a potent inhibitor of papillomavirus infection
Buck, C. B., Thompson, C. D., Roberts, J. N., Müller, M., Lowy, D. R., & Schiller, J. T. (2006) · PLoS Pathogens · doi:10.1371/journal.ppat.0020069 · Cited by 497
Self-citationGIANNINI, S., HANON, E., MORIS, P., VANMECHELEN, M., MOREL, S., DESSY, F., FOURNEAU, M., COLAU, B., SUZICH, J., & LOSONKSY, G. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.06.005 · Cited by 496
Human papillomavirus vaccine against cervical cancer: Opportunity and challenge
Wang, R., Pan, W., Jin, L., Huang, W., Li, Y., Wu, D., Gao, C., Ma, D., & Liao, S. (2020) · Cancer Letters · doi:10.1016/j.canlet.2019.11.039 · Cited by 493
Metadata
- Authors
- Pastrana, D. V., Buck, C. B., Pang, Y.-Y. S., Thompson, C. D., Castle, P. E., FitzGerald, P. C., Krüger Kjaer, S., Lowy, D. R., & Schiller, J. T.
- Venue
- Virology
- Publisher
- Elsevier BV
- Published
- 2004-04
- Volume
- 321
- Issue
- 2
- Pages
- 205-216
- ISSN
- 0042-6822 (ISSN-L)
- OpenAlex
- W2001429203
- Cited by
- 357
- References
- 34
- FWCI
- 11.71
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.